Enigma Biomedical Group Signs License Agreement with Merck for Novel MK-6884 Imaging Agent
Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884, an early stage investigational imaging agent developed by Merck for use in Positron Emission Tomography (PET) scans to measure cholinergic tone change in vivo.
- Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884, an early stage investigational imaging agent developed by Merck for use in Positron Emission Tomography (PET) scans to measure cholinergic tone change in vivo.
- Lee Ann Gibbs, President of Enigma Biomedical Group said, This is an important step in accelerating critical biomarker research projects globally.
- Toronto-based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine.
- Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group.